Cat. No.: DAB-0012365
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Cys361 of human NYAP1 protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | NYAP1 |
| UniProt No. | Q6ZVC0 |
| Gene ID | 222950 |
| Gene Description | Neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 1 is a member of the Nyap family of phosphoproteins, including NYAP1, NYAP2, and Myosin16/NYAP3. Upon stimulation by contactin5, NYAPs are phosphorylated by Fyn. Once phosphorylated, NYAP1, as well as other members of this family, interacts with PI3K p85 and active PI3K, Akt, and Rac1. The interaction of NYAP1 with WAVE complex mediates remodeling of the actin cytoskeleton after activation by PI3K-produced PIP3 and Rac1. The phosphorylation of NYAP1 directly contributes to normal neuronal migration and morphogenesis of neurons, acting downstream of Fyn, which is a non-receptor protein-tyrosine kinase that is a member of the Src kinase family. The overexpression of NYAP1 promotes neurite branching and elongation at early neuronal migration compared to the NYAP1-KO model. The lack of NYAP1 induces thinner leading neurites affecting the multibipolar morphology of neurons. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
